Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8849150 | 0.84 | IDO1 (0.56) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL8849145 | 0.84 | IDO1 (0.56) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL11165854 | 0.81 | IDO1 (0.57) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL18776419 | 0.81 | IDO1 (0.53) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL8375374 | 0.80 | IDO1 (0.54) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL1013 | 0.79 | IDO1 (0.62) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL37664 | 0.79 | HTR2A (0.62) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL2299037 | 0.78 | AKR1C3 (0.51) | IDO1RAB9AAKR1C3HTTHTR2A | |
| SCHEMBL1162336 | 0.77 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6399778 | 0.77 | IDO1 (0.59) | IDO1RAB9AAKR1C3HTTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | claimed |
| WO-2011140009-A1 | METHODS OF USING SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2373694-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BioMarin Pharmaceutical Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2010065174-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-4518773-A | \"3-Carbamoyloxy cephalosporins\ | BRISTOL-MYERS COMPANY (US) | 1985-05-21 | — | — | US | disclosed |
| US-4426520-A | CEPHALOSPORIN ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| US-4407755-A | BACTERICIDAL PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4374982-A | Cepham compounds | BRISTOL-MYERS COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4322347-A | 2-Carbamoyloxymethyl-penicillin derivatives | BRISTOL-MYERS COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | SI, FUT6, B3GAT3 | IDO1 541/4885RAB9A 2444/4885AKR1C3 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.